ZIOPHARM Oncology, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Sleeping Beauty (SB), which is based on the genetic engineering of immune cells using a non-viral transposon/transposase system to reprogram T-cells outside of the body for infusion; and Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to attack cancer cells. Its lead gene therapy product candidate is Ad-RTS-hIL-12 plus veledimex, which is in Phase I clinical trial, to treat patients with recurrent glioblastoma and breast cancer. The company is also developing chimeric antigen receptor (CAR) T-cell and T-cell receptor T-cell therapies. ZIOPHARM Oncology, Inc. has license agreement with Precigen, Inc. and MD Anderson Cancer Center; research and development agreement with the National Cancer Institute, and Ares Trading S.A. The company is headquartered in Boston, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone617-259-1970
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$150,000.00
Profitability
Miscellaneous
Employees48
Next Earnings Date5/9/2019 (Estimated)
OptionableOptionable
ZIOPHARM Oncology (NASDAQ:ZIOP) Frequently Asked Questions
What is ZIOPHARM Oncology's stock symbol?
ZIOPHARM Oncology trades on the NASDAQ under the ticker symbol "ZIOP."
How were ZIOPHARM Oncology's earnings last quarter?
ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) announced its quarterly earnings data on Wednesday, August, 8th. The biotechnology company reported ($0.12) EPS for the quarter, meeting the Zacks' consensus estimate of ($0.12). View ZIOPHARM Oncology's Earnings History.
When is ZIOPHARM Oncology's next earnings date?
What price target have analysts set for ZIOP?
3 analysts have issued 12-month price targets for ZIOPHARM Oncology's shares. Their forecasts range from $5.00 to $6.00. On average, they anticipate ZIOPHARM Oncology's stock price to reach $5.50 in the next twelve months. This suggests a possible upside of 35.1% from the stock's current price. View Analyst Price Targets for ZIOPHARM Oncology.
What is the consensus analysts' recommendation for ZIOPHARM Oncology?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ZIOPHARM Oncology in the last year. There are currently 1 sell rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for ZIOPHARM Oncology.
What are Wall Street analysts saying about ZIOPHARM Oncology stock?
Here are some recent quotes from research analysts about ZIOPHARM Oncology stock:
- 1. According to Zacks Investment Research, "ZIOPHARM Oncology, Inc. is a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for better patient treatment. " (12/20/2018)
- 2. HC Wainwright analysts commented, "We note that the biopsy analysis from the tumors of patients with rGBM, presented at SNO 2017, showed that Ad-RTS-hIL-12 plus veledimex monotherapy led to upregulation of PD-1 and PD-L1 receptors, suggesting a potential synergy between IL-12 and anti-PD-1 agents. Together with the shift to combinations, management also intends to expand the Ad-RTS-hIL-12 program beyond recurrent glioblastoma (rGBM) to include additional oncologic indications, such as breast cancer and melanoma. We note that the company plans to present an update of the biopsy analysis from the patients with rGBM and advanced breast cancer treated with Ad- RTS-hIL-12 plus veledimex at ASCO on June 4, 2018." (5/14/2018)
Has ZIOPHARM Oncology been receiving favorable news coverage?
Media coverage about ZIOP stock has been trending somewhat positive this week, according to InfoTrie. The research firm identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. ZIOPHARM Oncology earned a news impact score of 0.5 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 2.0 out of 10, meaning that recent press coverage is very unlikely to have an impact on the stock's share price in the near term.
Are investors shorting ZIOPHARM Oncology?
ZIOPHARM Oncology saw a increase in short interest in the month of February. As of February 28th, there was short interest totalling 41,837,510 shares, an increase of 1.5% from the February 15th total of 41,225,912 shares. Based on an average daily volume of 1,706,515 shares, the days-to-cover ratio is presently 24.5 days. Currently, 27.2% of the company's shares are sold short. View ZIOPHARM Oncology's Current Options Chain.
Who are some of ZIOPHARM Oncology's key competitors?
Some companies that are related to ZIOPHARM Oncology include Global Blood Therapeutics (GBT), Mirati Therapeutics (MRTX), Ligand Pharmaceuticals (LGND), Akcea Therapeutics (AKCA), Reata Pharmaceuticals (RETA), Emergent Biosolutions (EBS), Uniqure (QURE), PTC Therapeutics (PTCT), Zogenix (ZGNX), Insmed (INSM), Myokardia (MYOK), Biohaven Pharmaceutical (BHVN), Portola Pharmaceuticals (PTLA), Arena Pharmaceuticals (ARNA) and Ironwood Pharmaceuticals (IRWD).
What other stocks do shareholders of ZIOPHARM Oncology own?
Who are ZIOPHARM Oncology's key executives?
ZIOPHARM Oncology's management team includes the folowing people:
- Dr. Laurence James Neil Cooper, CEO & Director (Age 54)
- Dr. David M. Mauney M.D., Pres (Age 50)
- Mr. Kevin G. Lafond, Sr. VP of Fin., Chief Accounting Officer & Treasurer (Age 63)
- Ms. Lynn M. Ferrucci PHR, Sr. VP of HR, Facilities, IT & Admin.
- Mr. David Connolly, VP of Corp. Communications & Investor Relations
Who are ZIOPHARM Oncology's major shareholders?
ZIOPHARM Oncology's stock is owned by many different of institutional and retail investors. Top institutional shareholders include MSD Partners L.P. (7.72%), Third Security LLC (3.07%), Northern Trust Corp (1.16%), Geode Capital Management LLC (1.09%), Geode Capital Management LLC (1.09%) and Bank of New York Mellon Corp (0.40%). Company insiders that own ZIOPHARM Oncology stock include David M Md Mauney and Laurence James Neil Cooper. View Institutional Ownership Trends for ZIOPHARM Oncology.
Which institutional investors are selling ZIOPHARM Oncology stock?
ZIOP stock was sold by a variety of institutional investors in the last quarter, including Third Security LLC, Brown Advisory Inc., Barclays PLC, MetLife Investment Advisors LLC, Bank of New York Mellon Corp, G&S Capital LLC, Creative Planning and Virtus ETF Advisers LLC. View Insider Buying and Selling for ZIOPHARM Oncology.
Which institutional investors are buying ZIOPHARM Oncology stock?
ZIOP stock was purchased by a variety of institutional investors in the last quarter, including MSD Partners L.P., Ibex Investors LLC, Old West Investment Management LLC, Sargent Investment Group LLC, D. E. Shaw & Co. Inc., Geode Capital Management LLC, Geode Capital Management LLC and Two Sigma Investments LP. Company insiders that have bought ZIOPHARM Oncology stock in the last two years include David M Md Mauney and Laurence James Neil Cooper. View Insider Buying and Selling for ZIOPHARM Oncology.
How do I buy shares of ZIOPHARM Oncology?
Shares of ZIOP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ZIOPHARM Oncology's stock price today?
One share of ZIOP stock can currently be purchased for approximately $4.07.
How big of a company is ZIOPHARM Oncology?
ZIOPHARM Oncology has a market capitalization of $660.52 million and generates $150,000.00 in revenue each year. The biotechnology company earns $-53,120,000.00 in net income (profit) each year or ($0.48) on an earnings per share basis. ZIOPHARM Oncology employs 48 workers across the globe.
What is ZIOPHARM Oncology's official website?
How can I contact ZIOPHARM Oncology?
ZIOPHARM Oncology's mailing address is ONE FIRST AVENUE PARRIS BUILDING 34 NAVY YARD PLAZA, BOSTON MA, 02129. The biotechnology company can be reached via phone at 617-259-1970 or via email at [email protected]
MarketBeat Community Rating for ZIOPHARM Oncology (NASDAQ ZIOP)
MarketBeat's community ratings are surveys of what our community members think about ZIOPHARM Oncology and other stocks. Vote "Outperform" if you believe ZIOP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZIOP will underperform the S&P 500 over the long term. You may vote once every thirty days.
